{
    "organizations": [],
    "uuid": "9b91627f59ceb8065cfbb553c81a3f359a91b63a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-melinta-therapeutics-says-partner/brief-melinta-therapeutics-says-partner-commenced-new-program-for-topical-formulation-of-radezolid-in-preparation-for-submitting-ind-application-to-fda-idUSFWN1PD0Q6",
    "ord_in_thread": 0,
    "title": "BRIEF-Melinta Therapeutics Says ‍Partner Commenced New Program For Topical Formulation Of Radezolid, In Preparation For Submitting IND Application To FDA",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 18 (Reuters) - Melinta Therapeutics, Inc.:\n* MELINTA THERAPEUTICS - ‍PARTNER COMMENCED NEW PROGRAM FOR A TOPICAL FORMULATION OF RADEZOLID, IN PREPARATION FOR SUBMITTING AN IND APPLICATION TO FDA Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-18T20:13:00.000+02:00",
    "crawled": "2018-01-19T12:18:50.054+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "melinta",
        "therapeutic",
        "melinta",
        "therapeutic",
        "commenced",
        "new",
        "program",
        "topical",
        "formulation",
        "radezolid",
        "preparation",
        "submitting",
        "ind",
        "application",
        "fda",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}